Takeda Canada announced that FRUZAQLA - fruquintinib capsules - will now be reimbursed by BC Cancer as a treatment option for adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates, for available standard therapies.
FRUZAQLA was reimbursed in Quebec by Régie de l'assurance maladie, and under the federal Non-Insured Health Benefits Formulary, both under certain criteria patients need to meet. It received market authorization by Health Canada in September 2024 and received a positive reimbursement recommendation by Canada's Drug Agency and Institut national d'excellence en santé et services sociaux.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.